Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7807788 | 0.80 | MAPK1 (0.36) | MAPK1 | |
| SCHEMBL28641549 | 0.77 | CYP2C19 (0.31) | — | |
| SCHEMBL19491569 | 0.72 | MAPK1 (0.32) | MAPK1 | |
| SCHEMBL821634 | 0.72 | — | — | |
| SCHEMBL754933 | 0.72 | — | — | |
| SCHEMBL18572877 | 0.72 | — | — | |
| SCHEMBL14300789 | 0.70 | — | — | |
| SCHEMBL23772943 | 0.69 | MAPK1 (0.31) | MAPK1 | |
| SCHEMBL3835813 | 0.69 | — | — | |
| SCHEMBL17009051 | 0.68 | MAPK1 (0.44) | MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190294042-A1 | ACTINIC RAY-SENSITIVE OR RADIATION-SENSITIVE RESIN COMPOSITION, ACTINIC RAY-SENSITIVE OR RADIATION-SENSITIVE FILM, PATTERN FORMING METHOD, AND METHOD FOR MANUFACTURING ELECTRONIC DEVICE | FUJIFILM CORPORATION (JP) | 2019-09-26 | — | — | US | disclosed |
| US-7135491-B2 | 5-Aryltetrazole compounds and uses thereof | INOTEK PHARMACEUTICALS CORP. (US) | 2006-11-14 | — | — | US | disclosed |
| US-7087631-B2 | Aryltetrazole compounds, and compositions thereof | INOTEK PHARMACEUTICALS CORPORATION (US) | 2006-08-08 | — | — | US | disclosed |
| US-20060135519-A2 | 5-ARYLTETRAZOLE COMPOUNDS AND COMPOSITIONS THEREOF | NIVOROZHKIN ALEXANDER | 2006-06-22 | — | — | US | disclosed |
| US-20050159418-A1 | 5-Aryltetrazoles compounds and compositions thereof | NIVOROZHKIN ALEX (US) | 2005-07-21 | — | — | US | disclosed |
| US-20050159467-A1 | 5-Aryltetrazole compounds and uses thereof | NIVOROZHKIN ALEX (US) | 2005-07-21 | — | — | US | disclosed |
| EP-1542980-A1 | 5-ARYLTETRAZOLE COMPOUNDS, COMPOSITIONS THEREOF, AND USES THEREFOR | Inotek Pharmaceuticals Corporation (US) | 2005-06-22 | — | — | EP | disclosed |
| US-20040116423-A1 | 5-Aryltetrazole compounds, compositions thereof, and uses therefor | INOTEK PHARMACEUTICALS CORPORATION | 2004-06-17 | — | — | US | disclosed |
| WO-2004009563-A1 | 5-ARYLTETRAZOLE COMPOUNDS, COMPOSITIONS THEREOF, AND USES THEREFOR | INOTEK PHARMACEUTICALS CORPORATION (US) | 2004-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135519-A2 | 5-ARYLTETRAZOLE COMPOUNDS AND COMPOSITIONS THEREOF | CASP5, NOX5, IL5 | MAPK1 3217/4885 |
| US-20050159467-A1 | 5-Aryltetrazole compounds and uses thereof | NLRP3, XDH, CASP5 | MAPK1 3013/4885 |
| US-20050159418-A1 | 5-Aryltetrazoles compounds and compositions thereof | NLRP3, CASP5, CASP3 | MAPK1 3021/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.